title: Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo.
abstract: This study addresses a mechanism by which lymphocytes may promote vascular endothelial growth factor (VEGF) expression and angiogenesis in immune inflammation. Resting human umbilical endothelial cells (HUVECs) were found to express low levels of VEGF messenger RNA (mRNA) by reverse transcription polymerase chain reaction and ribonuclease protection assay with little or no change in expression following activation by cytokines, including tumor necrosis factor-alpha, interleukin (IL)-1, interferon gamma, or IL-4. In contrast, treatment of HUVECs and monocytes with soluble CD40 ligand (sCD40L) resulted in a marked dose-dependent induction of VEGF mRNA (approximately 4-fold), which peaked between 1 and 5 hours post-stimulation. Transient transfection of HUVECs was performed with a luciferase reporter construct under the control of the human VEGF promoter. Treatment of transfected HUVECs with sCD40L was found to enhance luciferase activity (approximately 4-fold) compared with controls, similar to the relative fold induction in mRNA expression in parallel cultures. Thus, CD40-dependent VEGF expression was a result of transcriptional control mechanisms. Treatment of HUVECs with sCD40L was also found to function in vitro to promote growth and proliferation in a VEGF-dependent manner, and CD40-dependent HUVEC growth was comparable to that found following treatment with recombinant human VEGF. Furthermore, subcutaneous injection of sCD40L in severe combined immunodeficient and nude mice induced VEGF expression and marked angiogenesis in vivo. Taken together, these findings are consistent with a function for CD40L-CD40 interactions in VEGF-induced angiogenesis and define a mechanistic link between the immune response and angiogenesis. (Blood. 2000;96:3801-3808)
authors.affiliation: The Division of Nephrology, Department of Medicine, Children's Hospital, Longwood, MA 02215, USA.
authors.forename: M
authors.initials: M
authors.lastname: Melter
authors.forename: M E
authors.initials: ME
authors.lastname: Reinders
authors.forename: M
authors.initials: M
authors.lastname: Sho
authors.forename: S
authors.initials: S
authors.lastname: Pal
authors.forename: C
authors.initials: C
authors.lastname: Geehan
authors.forename: M D
authors.initials: MD
authors.lastname: Denton
authors.forename: D
authors.initials: D
authors.lastname: Mukhopadhyay
authors.forename: D M
authors.initials: DM
authors.lastname: Briscoe
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D019013:CD40 Antigens / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology; D023201:CD40 Ligand / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D016207:Cytokines / Q000494:pharmacology; D004587:Electrophoresis, Agar Gel; D016228:Endothelial Growth Factors / Q000235:genetics / Q000378:metabolism; D004730:Endothelium, Vascular / Q000737:chemistry / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D008222:Lymphokines / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D009000:Monocytes / Q000737:chemistry / Q000187:drug effects*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011401:Promoter Regions, Genetic / Q000187:drug effects; D012333:RNA, Messenger / Q000096:biosynthesis / Q000187:drug effects; D012867:Skin / Q000098:blood supply / Q000737:chemistry / Q000187:drug effects; D016038:Skin Transplantation; D012995:Solubility; D014471:Umbilical Veins / Q000166:cytology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D019013:CD40 Antigens; D016207:Cytokines; D016228:Endothelial Growth Factors; D008222:Lymphokines; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D023201:CD40 Ligand